The FDA granted fast-track status to Sanofi Pasteur and KaloBios Pharmaceuticals' KB001A, an experimental treatment for Pseudomonas aeruginosa-related pneumonia among people being treated with mechanical ventilation. The drug, a monoclonal antibody, is undergoing an early-stage study in the U.S.
Pneumonia drug candidate wins fast-track designation from FDA
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||